Venturelli Alberto, Tagliazucchi Lorenzo, Lima Clara, Venuti Federica, Malpezzi Giulia, Magoulas George E, Santarem Nuno, Calogeropoulou Theodora, Cordeiro-da-Silva Anabela, Costi Maria Paola
Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Doctorate School in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, 41125 Modena, Italy.
Microorganisms. 2022 Jun 27;10(7):1298. doi: 10.3390/microorganisms10071298.
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, . Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reservoir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.
人类非洲锥虫病（昏睡病）和动物非洲锥虫病通常由相同的病原体引起，是被忽视的热带病。尽管在减少或消除人类非洲锥虫病病例方面取得了重要进展，但动物非洲锥虫病仍是感染的一个危险储存库。正如欧盟委员会在最近一份关于保留用于人类的抗菌药物的文件中所主张的，迫切需要控制动物非洲锥虫病。控制动物非洲锥虫病被视为粮农组织防治非洲锥虫病计划确立的“同一健康”方法的一部分。在“同一健康”概念的框架下，在这项工作中，通过分析针对 种的治疗选择的药理学特性，我们强调在使用针对人类非洲锥虫病和动物非洲锥虫病的药物时需要更清晰、更明确的指导方针。提出了基本要求以应对药物使用和耐药性发展的挑战。这种方法应避免种间交叉耐药现象并保留药物的治疗活性。
